BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15

• Press Releases

  Biovica Receives Ninth Work Order From a Leading Global Pharmaceutical Customer

  July 14, 2026

   · 

  2 min read
• Press Releases

  AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability

  July 14, 2026

   · 

  19 min read
• Press Releases

  Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

  July 14, 2026

   · 

  10 min read
• Press Releases

  Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

  July 14, 2026

   · 

  10 min read
• Press Releases

  Actineer Achieves Sustainable Radium-226 Recycling to Advance Reliable Commercial-Scale Production of Actinium‑225 for Global Radiopharmaceutical Programs

  July 14, 2026

   · 

  5 min read
• Press Releases

  Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome

  July 14, 2026

   · 

  8 min read
• Press Releases

  InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLL

  July 14, 2026

   · 

  3 min read
• Press Releases

  Axiom Biosciences Reports Positive Phase 1 Results for Investigational Stem Cell Therapy in Newborns with Severe Brain Injury

  July 14, 2026

   · 

  3 min read
• Press Releases

  Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.

  July 14, 2026

   · 

  9 min read
• Press Releases

  Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

  July 14, 2026

   · 

  6 min read